CN1185331A - High-effective Naoxinning medicine for curing cerebrovascular disease - Google Patents
High-effective Naoxinning medicine for curing cerebrovascular disease Download PDFInfo
- Publication number
- CN1185331A CN1185331A CN96117334A CN96117334A CN1185331A CN 1185331 A CN1185331 A CN 1185331A CN 96117334 A CN96117334 A CN 96117334A CN 96117334 A CN96117334 A CN 96117334A CN 1185331 A CN1185331 A CN 1185331A
- Authority
- CN
- China
- Prior art keywords
- medicine
- effective
- blood
- naoxinning
- positive reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract description 7
- 241000628997 Flos Species 0.000 claims description 18
- 241000208340 Araliaceae Species 0.000 claims description 13
- 208000018152 Cerebral disease Diseases 0.000 claims description 13
- 241000237903 Hirudo Species 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- 239000000470 constituent Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 238000011282 treatment Methods 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 6
- 102000008946 Fibrinogen Human genes 0.000 abstract description 5
- 108010049003 Fibrinogen Proteins 0.000 abstract description 5
- 229940012952 fibrinogen Drugs 0.000 abstract description 5
- 241000545744 Hirudinea Species 0.000 abstract description 4
- 241000112528 Ligusticum striatum Species 0.000 abstract description 4
- 241000758794 Asarum Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000000295 complement effect Effects 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000007789 gas Substances 0.000 description 15
- 239000007902 hard capsule Substances 0.000 description 12
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FYRHTIWFKXZWAD-UHFFFAOYSA-N Sarisan Chemical compound C1=C(CC=C)C(OC)=CC2=C1OCO2 FYRHTIWFKXZWAD-UHFFFAOYSA-N 0.000 description 6
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- -1 quinone glycoside Chemical class 0.000 description 6
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 229940116837 methyleugenol Drugs 0.000 description 5
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000017965 Asarum canadense Nutrition 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 235000000385 Costus speciosus Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 241000606265 Valeriana jatamansi Species 0.000 description 3
- 235000014687 Zingiber zerumbet Nutrition 0.000 description 3
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 229930006739 camphene Natural products 0.000 description 3
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 2
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 2
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 2
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 2
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 2
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 description 2
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 2
- KFUCYPGCMLPUMT-UHFFFAOYSA-N perlolyrine Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1NC1=CC=CC=C21 KFUCYPGCMLPUMT-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 239000001054 red pigment Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229940109990 ruscogenin Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- CHBNMKPHUSAEJE-KQLJZIGXSA-N 2,6,6-trimethyl-3-(2,6,6-trimethyl-3-bicyclo[3.1.1]hept-1-enyl)-3-[(3R)-2,6,6-trimethyl-3-bicyclo[3.1.1]hept-1-enyl]bicyclo[3.1.1]hept-1-ene Chemical compound C12=C([C@@H](CC(C1(C)C)C2)C1(C(=C2C(C(C1)C2)(C)C)C)C1C(=C2C(C(C1)C2)(C)C)C)C CHBNMKPHUSAEJE-KQLJZIGXSA-N 0.000 description 1
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 description 1
- JQSVHBFDZXZENO-UHFFFAOYSA-N 3-butyl-4-hydroxy-3h-2-benzofuran-1-one Chemical compound C1=CC(O)=C2C(CCCC)OC(=O)C2=C1 JQSVHBFDZXZENO-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000758795 Aristolochiaceae Species 0.000 description 1
- 241001472196 Asarum heterotropoides Species 0.000 description 1
- 241001289295 Asarum sieboldii Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000448280 Elates Species 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000237678 Hirudinidae Species 0.000 description 1
- 241000146385 Hirudo nipponia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- YYSRTHIUABRSAB-UHFFFAOYSA-N Neocarthamin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(O)C2=C1C(=O)CC(C=1C=CC(O)=CC=1)O2 YYSRTHIUABRSAB-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241001431359 Whitmania acranulata Species 0.000 description 1
- 241000258623 Whitmania pigra Species 0.000 description 1
- PFRUBEOIWWEFOL-UHFFFAOYSA-N [N].[S] Chemical compound [N].[S] PFRUBEOIWWEFOL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- IRAQOCYXUMOFCW-CXTNEJHOSA-N cedrene Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@H]1C(C)=CC2 IRAQOCYXUMOFCW-CXTNEJHOSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IRAQOCYXUMOFCW-UHFFFAOYSA-N di-epi-alpha-cedrene Natural products C1C23C(C)CCC3C(C)(C)C1C(C)=CC2 IRAQOCYXUMOFCW-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 108010021337 lipoprotein triglyceride Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N methyl ethyl ketone Substances CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- UBFTZAGDGOMJQE-SACPXRHSSA-N neocarthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C(O)=CC2=C1C(=O)C[C@@H](C=1C=CC(O)=CC=1)O2 UBFTZAGDGOMJQE-SACPXRHSSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001792 thromboblast Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a high-effective Naoxinning for curing angiocardiopathy and cerebrovascular disease. The formula mainly comprises leech, asarum and ligusticum wallichii. The composition has effects of remarkably reducing fibrinogen and blood lipid, and reducing platelet aggregation and plasma specific viscosity. It not only retains the advantages of the traditional Chinese medicines, but also has the synergistic and complementary effects, reduces the side effects of the medicines and increases the treatment efficiency. Through clinical application, the medicine is safe and effective, and is an ideal medicine for preventing and treating cerebrovascular diseases.
Description
The invention belongs to the Chinese medicine class, what relate generally to is a kind of high-effective Naoxinning-medicine for curing cardio-cerebral disease for the treatment of cardio-cerebrovascular disorder.
Cardio-cerebrovascular disorder is the healthy formidable enemy of current harm humans, also is simultaneously to cause one of human dead important diseases.Research report shows: viscosity of blood increases, it is the important step of the generation and the development of ischemic cerebral vascular, and platelet aggregation and ischemic cerebrovascular are in close relations, hematoblastic aggregation capability has important effect in blood flow hemostasis and thrombosis, the maximum poly-rate of platelet is to weigh the sensitive indicator of platelet aggregation; Plasma viscosity is decided by the content of macromole composition in the blood plasma (Fibrinogen, cholesterol, B-lipoprotein, triglyceride, albumin etc.) to a great extent.Applied clinically hemorheological detection can disclose the viscosity of blood, hematoblastic aggregation rate etc. to people, and then can forecast the omen of apoplexy, thereby take proper prophylactic methods.At present, though clinical Therapeutic Method that cardio-cerebrovascular disorder is taked and the drug variety taken are a lot, general curative effect is not satisfactory.
Purpose of the present invention promptly produces thus, proposes a kind of high-effective Naoxinning-medicine for curing cardio-cerebral disease that can significantly reduce Fibrinogen and blood fat, reduction platelet aggregation and plasma viscosity.Can play benefiting QI for activating blood circulation, blood stasis dispelling the turbid descending, dispelling, collateral-activating, the thrombotic effect of prevention of brain by taking this medicine.
For achieving the above object, the present invention is in theory of Chinese medical science thought: under the guidance of " monarch, minister, help, make and treating both the principal and secondary aspects of a disease ", through clinical repeatedly practising, on the basis of a large amount of screenings, demonstration, it is as follows to provide formula constituent of the present invention: it is that main component is formed with Hirudo, Herba Asari, Rhizoma Chuanxiong mainly.
The present invention also can add Flos Carthami, Radix Ginseng, Rhizoma Gastrodiae component in filling a prescription and forming.
During the present invention filled a prescription and forms, the amount ranges of Hirudo, Herba Asari, Rhizoma Chuanxiong (percentage ratio) was respectively: Hirudo 15-40%, Herba Asari 5-10%, Rhizoma Chuanxiong 7-50%.
The amount ranges (percentage ratio) that adds Flos Carthami, Radix Ginseng, Rhizoma Gastrodiae during the present invention fills a prescription and forms is respectively: Flos Carthami 10-20%, Radix Ginseng 8-28%, Rhizoma Gastrodiae 10-30%.
The present invention is a monarch drug with Hirudo, Flos Carthami in filling a prescription and forming, and main function: removing blood stasis leads to the stasis of blood, and clinical practice proves that this medicine has blood viscosity lowering, blood flow increasing, and microcirculation improvement can prevent cerebral thrombosis.Radix Ginseng is a ministerial drug, and merit strengthens the effect of activating blood and removing stasis drug in QI invigorating, " qi as the commander of blood ", " blood being the mother of qi ", " the capable then blood of gas is capable, and gas ends then blood clotting ", and ginseng qi-tonifying just is to promote blood and accelerates the circulation effect.Rhizoma Gastrodiae, Herba Asari are adjuvant drug, have the effect of the turbid descending that dispels the wind, understand things pain-stopping, can directly treat the numb limbs and tense tendons that occurs owing to blood viscosity is too high, dizzy, pain, disease such as jolt.Rhizoma Chuanxiong is a messenger drug, can draw the through sick institute of all medicines, simultaneously Rhizoma Chuanxiong is again the medicine of promoting blood circulation by removing wind simply, be the gas medicine in the blood, have blood-activating and qi-promoting, diffusing wind analgesic effect, modern age, relevant pharmacological research confirmed, Rhizoma Chuanxiong contains a large amount of ligustrazine, be blood vessel dilating, blood flow increasing, the important drugs of reduction blood viscosity.
On the other hand on the treating both the principal and secondary aspects of a disease angle of the traditional Chinese medical science, think blood circulation promoting and blood stasis dispelling, blood fat reducing the turbid descending, increase blood circulation, microcirculation improvement be primary disease treatment this.With Hirudo, Flos Carthami, Rhizoma Chuanxiong master it, with circulation of qi promoting, dispel the wind, collateral dredging, pain relieving, improve the mark that symptom is a primary disease.Common symptom such as numb limbs and tense tendons, dizzy, weak, uncomfortable in chest, breathe hard, myalgia etc.With masters' such as Rhizoma Gastrodiae, Herba Asari, Radix Ginseng, Rhizoma Chuanxiong.Get in touch each other between the two clinically, influence each other,, complement each other so in treatment, interact.As dispel the wind and invigorate blood circulation, circulation of qi promoting and blood stasis dispelling, invigorate blood circulation and pain relieving etc. usually links together, can reach simple medication again and be good result.
The chemical constituent and the physicochemical property of medicine of the present invention are as follows:
1, Hirudo is the dry body of Hirudinidae animal whitmania Whitmania Pigra Whitman Hirudo Hirudo nipponia whiawan or Folium Salicis Babylonicae Hirudo Whitmania acr-anulata Whiaman.Containing hirudin (hirudin) in the glandula of Hirudo, is a kind of by last elementary composition acid substance such as carbon, hydrogen, nitrogen sulfur, soluble in water.In addition, contain a kind of H-subst and heparin (hep-arim) etc. in its secretions.
2, Flos Carthami is the dried floral of feverfew Flos Carthami Carthamus tinctoricusl.Flos Carthami contains glycoside such as Flos Carthami quinone glycoside, neocarthamin and Flos Carthami glycoside.Flos Carthami contains the reddening flavochrome.Isolate red pigment and flavochrome from pigment, these two kinds of compositions are unstable, and wherein red pigment is heated and easily changes, poor stability in hot solution.In addition, Flos Carthami also contains 6-hydroxyl Rhizoma Kaempferiae flavin, Rhizoma Kaempferiae flavin 3-grape glucoside, Quercetin 3-grape glucoside, Quercetin 7-grape glucoside, Rhizoma Kaempferiae flavin 3-rutinoside and globulariacitrin.
3, Rhizoma Gastrodiae is the dry rhizome of orchid Rhizoma Gastrodiae Gastrodia elate blame.Rhizoma Gastrodiae contains the yarn category-A material of supporting one's family, and the blue alcohol of fragrant folder, the blue aldehyde of fragrant folder also separablely from Rhizoma Gastrodiae go out gastrodine (gastrodin), and this is a main component in the Rhizoma Gastrodiae.Contain gastrodin unit one p-Hydroxybenzylalcohol, cupreol etc. in addition.Main Ingredients and Appearances such as gastrodine are soluble in water, so adopt the finished product of water-boiling method processing, content is lower, and to rub peeling back decocting in water person with the hands, gastrodine reduces at most especially, even the sample that has reduces to 0, and contain a large amount of gastrodine in the decoction liquor.
4, Rhizoma Chuanxiong is the dry rhizome of samphire Rhizoma Chuanxiong (igusticum chmamxiong hort), contains volatile oil, alkaloid, phenolic substance, neutral substance (lactone), organic acid etc.Alkaloid partly has ligustrazine (tetrame thylpyazine) isoleucyl-valine lactams and secalin (Perlolyrine), belongs to 1 β-0 carboline derivative.The phenol part is by ferulic acid, chrysophanol, sedanoic acid and 4-hydroxyl-3-butylphthalide; The volatile oil chemical analysis mainly is Rhizoma Ligustici lactone (containing 58%), 3-butylidenephthalide (5.29%) and Cedrene (6.08%) etc.
5, Herba Asari is aristolochiaceae plant Herba Asari Asarum heterotropoi-des Frvar mandshuricum (Maxim) Kitag, the dry herb of Seoul Herba Asari AsarumSieboldii Miq var seoulense Nakai or magnificent Herba Asari Asarum Sibol-dii Miq.Herba Asari contains volatile oil about 3%, Main Ingredients and Appearance methyleugenol (methyleugend), other composition has australene, camphene, myrcene, 1.8-cineole (1,8-Cineole), to poly-umbrella ellagic acid (P-C-Ymene) r-terpinene (r-terqinene), terpinolene (terpinolene), imperial disengaging, safrole, methyleugenol, asaricin etc.China's Herba Asari contains volatile oil 2.75%, and Main Ingredients and Appearance contains methyleugenol (accounting for 50%).Other composition has australene, camphene, nopinene, myrcene, and 1,8-presses foline, Borneolum Syntheticum, safrole methyleugenol, asaricin etc.Contain australene, camphene, acetic acid bornyl ester, safrole, methyleugenol, asaricin etc. in the Herba Asari volatile oil of Seoul.In addition, the metal ion total content is 20360PPm in the Herba Asari, and zinc, copper ratio are 9.5, contain elements such as potassium, sodium, magnesium, calcium, ferrum, manganese, copper, zinc.
6, Radix Ginseng: be the dry root of Araliaceae Radix Ginseng Panaxginseng C, A, Mey.It is about 4% that root contains general glycoside, and content is the mixture of Saponin more than 14 kinds than the main root height in the fibrous root, is called ginsenoside Ro, Ra
1, Ra
1, Rb
1, Rb
2, Rc, Rd, Re, Rf, Rg
1, Rg
2, Rb
1Deng, be triterpenoid saponin.Be main active ingredient, wherein Ra wherein with agate methane series Saponin
1, Ra
1, Rb
1, Rb
2, Rb
3, Rc, Rd etc., produce the panoxadiol behind the sour water dry measure used in former times, Re, Rf, Rg
1, Rg
2, produce the panaxatriol behind the water dry measure used in former times such as Rh.Ro is an olive methane series Saponin, and its ruscogenin is an oleanolic acid.It is equal 0.12% to contain volatile oil, and composition has the fragrant alkene of β-pull (β-Ele-meae), Panaxynol (Pamawynol) and many epoxy materials panaxynol (Pamawy-dol) etc. in the oil.In addition, still contain multiple low molecular peptide, aminoacid, monosaccharide, disaccharidase, three polysaccharide, organic acid, vitamin B group, vitamin C, cupreol and glycoside thereof.Ginsenoside's great majority are that white amorphous powder or colourless pin are prosperous, little sweetness and bitterness of distinguishing the flavor of, have draw moist.Generally to acid unstable (except the ginsenoside Ro), weak acid down can the water dry measure used in former times, but can not get real original shape ruscogenin behind the water dry measure used in former times, and soluble in water, methanol, ethanol dissolve in n-butyl alcohol, acetic acid, ethyl acetate, is insoluble to ether, benzene.Panaxoside Rg
1, molecular formula C
42H
72O
14, molecular weight 800, uv goes into neor208, is colourless hypocrystalline thing (n-butyl alcohol-methyl ethyl ketone), mp194-196.5 ℃ [d]
115+ 320 (pyridines).Be dissolved in methanol, pyridine and hot acetone, be dissolved in ethyl acetate and chloroform slightly.Rats by intraperitoneal injection 10mg/Kg, the biosynthesis of the DNA of medullary cell obviously increases after 4 hours, to the biosynthesis effect of protein or fat with the biosynthetic effect of DAN is had roughly the same tendency.
Preliminarily stabilised result of the test of the present invention is as follows:
Medicine preliminarily stabilised test report
| Standing time (experiment date) is project as a result | 0 month (on March 7th, 95) | January (on April 7th, 95) | February (on May 10th, 95) | March (on June 10th, 95) | |
| Character | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | This product is a hard capsule, and content is the salty little hardship of the pale brown toner fragrant little fishy smell of end gas | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | |
| Outward appearance | Up to specification | Up to specification | Up to specification | Up to specification | |
| Differentiate | 1, Flos Carthami | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction |
| 2, Rhizoma Chuanxiong | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction | |
| 3, Herba Asari | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction | |
| Differentiate | Moisture content (%) | ??5.7 | ??5.7 | ??5.8 | ??5.9 |
| Disintegration | ??11′ | ??12′ | ??13′ | ??13′ | |
| Content uniformity | Up to specification | Up to specification | Up to specification | Up to specification | |
| Assay (mg/g) | ??0.129 | ??0.128 | ??0.131 | ??0.127 | |
Medicine preliminarily stabilised test report
| Standing time (experiment date) is project as a result | 0 month (on March 7th, 95) | January (on April 7th, 95) | February (on May 10th, 95) | March (on June 10th, 95) | |
| Character | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | |
| Outward appearance | Up to specification | Up to specification | Up to specification | Up to specification | |
| Differentiate | 1, Flos Carthami | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction |
| 2, Rhizoma Chuanxiong | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction | |
| 3, Herba Asari | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction | |
| Differentiate | Moisture content (%) | ??5.7 | ??5.8 | ??5.8 | ??5.9 |
| Disintegration | ??11′ | ??12′ | ??12′ | ??12′ | |
| Content uniformity | Up to specification | Up to specification | Up to specification | Up to specification | |
| Assay (mg/g) | ??0.134 | ??0.137 | ??0.131 | ??0.128 | |
Medicine preliminarily stabilised test report
| Standing time (experiment date) is project as a result | 0 month (on March 7th, 95) | January (on April 7th, 95) | February (on May 10th, 95) | March (on June 10th, 95) | |
| Character | This product is a hard capsule, and content is the salty little hardship of the pale brown toner fragrant little fishy smell of end gas | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | This product is a hard capsule, and content is the salty little hardship of the pale brown toner fragrant little fishy smell of end gas | This product is a hard capsule, and content is that gas fragrant little fishy smell in pale brown toner end becomes little hardship | |
| Outward appearance | Up to specification | Up to specification | Up to specification | Up to specification | |
| Differentiate | 1, Flos Carthami | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction |
| 2, Rhizoma Chuanxiong | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction | |
| 3, Herba Asari | Be positive reaction | Be positive reaction | Be positive reaction | Be positive reaction | |
| Differentiate | Moisture content (%) | ??5.9 | ??5.9 | ??5.8 | ??5.9 |
| Disintegration | ??14′ | ??14′ | ??13′ | ??14′ | |
| Content uniformity | Up to specification | Up to specification | Up to specification | Up to specification | |
| Assay (mg/g) | ??0.123 | ??0.127 | ??0.125 | ??0.124 | |
Toxicity test of the present invention is as follows:
Long term toxicity test:
60 of the healthy Wistar rats of animal subject, male and female half and half, body weight 91 ± 14g.Rat is divided into three groups of A, B, C at random, 20 every group, male and female half and half, dosage is grouped into:
A organizes (matched group): 5% cmc soln (2.25ml/100g body weight).
B group: high-effective Naoxinning-medicine for curing cardio-cerebral disease 3.0g/Kg body weight (13.33%, 2.25ml/100g body weight).
C group: high-effective Naoxinning-medicine for curing cardio-cerebral disease 1.5g/Kg body weight (6.665%, 2.25ml/100g body weight).
The above-mentioned perfusion amount of respectively organizing is decided with the body weight variation.Irritate stomach every day once, continuous six days, take a day off three totally months.Irritate the stomach amount weekly according to the body weight change adjustment once, after three months, each group is got 10 rats at random and is put to death, and gathers jugular vein blood, measures the routine blood test index, biochemical indicator, dirty body ratio and histopathologic examination.Experimental result shows: this medicine does not have harmful effect to rat growthing development and the heart, brain, kidney, adrenal gland, spleen, genital organ etc., does not observe the influence to blood system yet, and renal function is normal.Can cause that rat liver increases but take for a long time, abnormal liver function, but do not see pathological change, the excessive life-time service of dosage can cause the induced lung internal hemorrhage.
Acute toxicity testing:
20 of animal subject Kunming mouses, body weight 20-22g, male and female half and half.With 5% hydroxy methocel as excipient, compound concentration is 10% high-effective Naoxinning-medicine for curing cardio-cerebral disease suspension (surpass this concentration and can't pour into the mice gastric), every 10g body weight mice stomach amount is 0.4ml, and promptly the administration maximal dose is the 4g/Kg body weight, divides to pour into for early, middle and late three times in 1 day.The experiment structure shows: irritate behind the stomach that tiredly contracting appears in mice, the movable minimizing, after 1 day activity freely, diet is normal, observes continuously seven days, does not see death.Only, observe two mice nasal cavity and a small amount of courageous and upright secretions occurs, recover normal after three days in irritating stomach second day.
Clinical observation on the therapeutic effect of the present invention is as follows:
It is the cerebrovascular patient of blood high viscosity syndrome that this group case is all gone to a doctor through the hemorheology inspection through Neurology Department, in 308 examples, man's 182 examples, woman's 126 examples, age 26-78 year, average 59 years old, cerebral thrombosis 124 examples, cerebral hemorrhage 68 examples, TIA42 example, (diagnostic criteria was according to second neural psychiatric department in the whole nation in 1978 for cerebral arteriosclerosis 74 examples, academic conference is about the diagnostic point of cerebrovascular), the shortest person of the course of disease 6 hours, elder 9 years, have 192 examples to do the head CT inspection, wherein 102 routine focal zones are that low-density shade 62 examples have brain atrophy.
Therapeutic Method:
According to the hemorheology check result, take efficient anti-bolt sheet, every day three times, each 1-3 sheet, one month one is the course of treatment.Check hemorheology after the course of treatment, stopping using at viewing duration, all influence the medicine that blood becomes.
Observation of curative effect:
Observation of curative effect comprises that brain function changes and hemorheology changes two parts.Table 1:
Efficient anti-bolt sheet is to brain function influence observation (308 example)
Effective percentage reaches 92.42%
| Headache and dizzy | Stagger | The dyskinesia | Dysarthria | Sensory disturbance | Ataxia | Visual disorder | Bulbar paralysis | ||
| Before the treatment | 273 | ?32 | 117 | ?28 | ?65 | ?19 | ?17 | ?26 | |
| Treatment back example | Cure | 187 | ?18 | ?51 | ?12 | ?32 | ??7 | ??5 | ?11 |
| Take a turn for the better | ?65 | ?12 | ?57 | ?14 | ?28 | ?10 | ?11 | ?13 | |
| Invalid | ?21 | ??2 | ??9 | ??2 | ??5 | ??2 | ??1 | ??2 | |
Hemorheology index is measured before and after the efficient anti-bolt sheet treatment
Mean+SD
Whole blood is than rear 5.17 ± 0.62 1.52 ± 0.06 46.65 ± 0.9 20.20 ± 2.0 52.06 ± 2.24 349.16 ± 7.2P value＜0.05＜0.01＞0.05＞0.05＜0.01＜0.01 of front 5.98 ± 0.72 1.86 ± 0.07 49.10 ± 1.10 23.62 ± 1.96 72.10 ± 2.50 442.36 ± 1.42 treatments of the former mg/% treatment of blood plasma red blood cell erythrocyte sedimentation rate blood platelet fiber egg treatment stage viscosity (ratio) viscosity (ratio) hematocrit % mm/n PAR % blood
Table 3: blood fat changes before and after the efficiently anti-bolt sheet treatment
Mean+SD
Cholesterol B～lipoprotein triglyceride treatment stage (mg%) is 182.3 ± 2.12 301.17 ± 8.22 107.91 ± 3.27 P value＜0.1＜0.01＜0.01, preceding 247.2 ± 3.12 396.22 ± 7.39 149.06 ± 4.12 treatment backs of (mg%) treatment (mg%)
Clinical practice is the result show: high-effective Naoxinning-medicine for curing cardio-cerebral disease can reduce platelet aggregation rate and blood plasma viscosity, reduce Fibrinogen and blood fat, viscosity of blood is descended, the brain blood circulation improves, and then improving brain function, clinical manifestation disappears for headache, dizzy phenomenon, and extremity motor function also recovers gradually and takes a turn for the better.Increase (72.10 ± 2.50%) taking high-effective Naoxinning-medicine for curing cardio-cerebral disease thromboblast aggressiveness rate, the obviously decline (52.06 ± 2.24%) of treatment back, learn by statistics and handle, significant difference (P＜0.01) is arranged, because platelet aggregation decline, suppressed thrombotic early stage link, thereby the thrombotic effect of prevention has been arranged.The Fibrinogen meansigma methods is reduced to 349.16 ± 7.2mg% by 442.36 ± 1.42mg% before and after taking high-effective Naoxinning-medicine for curing cardio-cerebral disease, number is handled by statistics, significant difference (P＜0.01) is arranged, cholesterol, B-lipoprotein and triglyceride all have obvious decline after treatment, plasma viscosity is than dropping to 1.52 ± 0.06 by 1.80 ± 0.07.
The present invention adopts the traditional handicraft method to manufacture, and can produce to be capsule or tablet.It had both kept Chinese medicine advantage separately, and the collaborative effect that complements one another is arranged again.Reduced the medicine effect of paying separately, increased therapeutic effect, through clinical practice, safety, effective is a kind of ideal medicament of prevention and treatment cerebrovascular disease.
The specific embodiment that the present invention provides is as follows:
Embodiment 1
The component consumption
Hirudo 4.5%
Herba Asari 5%
Rhizoma Chuanxiong 50%
Embodiment 2: component consumption leech 30% safflower 15% ginseng 20% rhizoma Gastrodiae 15% root of Chinese wild ginger 5% Ligusticum wallichii 15% embodiment 3 component consumption leech 25% root of Chinese wild ginger 10% Ligusticum wallichii 40% safflower 25% embodiment 4 component consumption leech 20% root of Chinese wild ginger 10% Ligusticum wallichii 30% safflower 15% ginseng 25%
Claims (4)
1, a kind of high-effective Naoxinning-medicine for curing cardio-cerebral disease is characterized in that: formula constituent of the present invention includes Hirudo, Herba Asari, Rhizoma Chuanxiong component.
2, high-effective Naoxinning-medicine for curing cardio-cerebral disease according to claim 1 is characterized in that: also can add Flos Carthami, Radix Ginseng, Rhizoma Gastrodiae component at the same time or separately in above-mentioned formula constituent.
3, high-effective Naoxinning-medicine for curing cardio-cerebral disease according to claim 1 is characterized in that: the amount ranges of described Hirudo, Herba Asari, Rhizoma Chuanxiong component is respectively: Hirudo 15-40%, Herba Asari 5-10%, Rhizoma Chuanxiong 7-50%.
4, high-effective Naoxinning-medicine for curing cardio-cerebral disease according to claim 2 is characterized in that: the amount ranges of described Flos Carthami, Radix Ginseng, Rhizoma Gastrodiae component is respectively: Flos Carthami 10-20%, Radix Ginseng 8-28%, Rhizoma Gastrodiae 10-30%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96117334A CN1059103C (en) | 1996-12-20 | 1996-12-20 | Medicine for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96117334A CN1059103C (en) | 1996-12-20 | 1996-12-20 | Medicine for treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1185331A true CN1185331A (en) | 1998-06-24 |
| CN1059103C CN1059103C (en) | 2000-12-06 |
Family
ID=5124216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96117334A Expired - Fee Related CN1059103C (en) | 1996-12-20 | 1996-12-20 | Medicine for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1059103C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198162A (en) * | 2011-06-03 | 2011-09-28 | 广东药学院 | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof |
| CN104127706A (en) * | 2014-07-04 | 2014-11-05 | 万光瑞 | Traditional Chinese medicinal preparation for holistically treating cardio-cerebrovascular diseases of old people, and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1122243A (en) * | 1995-08-16 | 1996-05-15 | 岳泰出 | Medicinal powder for eliminating embolism and invigorating blood circulation |
-
1996
- 1996-12-20 CN CN96117334A patent/CN1059103C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198162A (en) * | 2011-06-03 | 2011-09-28 | 广东药学院 | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof |
| CN102198162B (en) * | 2011-06-03 | 2013-06-19 | 广东药学院 | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof |
| CN104127706A (en) * | 2014-07-04 | 2014-11-05 | 万光瑞 | Traditional Chinese medicinal preparation for holistically treating cardio-cerebrovascular diseases of old people, and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1059103C (en) | 2000-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qin et al. | Pharmacological activities and pharmacokinetics of liquiritin: a review | |
| Abdollahi et al. | Antinociceptive effects of Teucrium polium L. total extract and essential oil in mouse writhing test | |
| Ma et al. | Non-polyphenolic natural inhibitors of amyloid aggregation | |
| Tang et al. | A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia | |
| US10238676B2 (en) | Application of ginsenoside RG3 in preparing medicine for preventing and/or treating dementia, and medicine for treating dementia | |
| PT1331007E (en) | Chinese herbs extract | |
| Song et al. | Traditional Chinese Medicine Li-Zhong-Tang accelerates the healing of indomethacin-induced gastric ulcers in rats by affecting TLR-2/MyD88 signaling pathway | |
| CN108186877A (en) | For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention | |
| Wan et al. | Multiple effects of ginseng berry polysaccharides: Plasma cholesterol level reduction and enteric neoplasm prevention | |
| Li | Chinese herbal medicine | |
| CN1059103C (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| Wang et al. | Qingfei xieding prescription ameliorates mitochondrial DNA-initiated inflammation in bleomycin-induced pulmonary fibrosis through activating autophagy | |
| CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
| CN115414458B (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
| CN102526157B (en) | Application of safflower extract to prevention or treatment of neurodegeneration disease | |
| JPS626687B2 (en) | ||
| Jiang et al. | Effect fraction of Bletilla striata (Thunb.) Reichb. f. alleviates LPS-induced acute lung injury by inhibiting p47phox/NOX2 and promoting the Nrf2/HO-1 signaling pathway | |
| CN1579485B (en) | Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof | |
| CN102058825B (en) | Traditional Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| CN103142695B (en) | Pharmaceutical composition for prevention and treatment of chronic glomerular diseases and preparation method of pharmaceutical composition | |
| Sisay et al. | Glinus lotoides linn. Seed extract as antidiabetic agent: In vitro and in vivo anti-glucolipotoxicity efficacy in Type-II diabetes mellitus | |
| Badmaev et al. | The therapeutic effect of an herbal formula Badmaev 28 (padma 28) on experimental allergic encephalomyelitis (EAE) in SJL/J mice | |
| CN1857395A (en) | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases | |
| CN101073598A (en) | Medicinal composition for treating cardiovascular and cerebrovascular disease and its preparation | |
| CN103933386A (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |